To investigate the potential of PIM1 as a therapeutic target in ALK-positive NB, transcript levels of PIM1 were assessed by RT-qPCR across 25 NB cell lines that are diverse with respect to ALK and MYCN status (Fig. 3a). This evidence concerns the gene PIM1 and neuroblastoma.